Related Experiment Video
Updated: Feb 13, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells
Niradiz Reyes1,2, Ines Benedetti1,3, Juan Rebollo1,4
1Department of Basic Sciences, School of Medicine, University of Cartagena, Cartagena, Colombia.
Abstract:
Atypical chemokine receptors have recently emerged as important molecular players in health and diseases; they affect chemokine availability and function and impact a multitude of pathophysiological events, including the tumorigenesis process. This family of atypical receptors comprises five members: ACKR1/DARC, ACKR2/D6, ACKR3/CXCR7, ACKR4/CCRL1, and ACKR5/CCRL2. This work evaluated the differential expression of these receptors in prostate cancer using quantitative PCR. Further evaluation of CCRL2 at the protein level confirmed its overexpression in a metastatic cell line and in malignant prostatic tissues from patients. CCRL2, a presumed member of the atypical chemokine receptor family, plays a key role in lung dendritic cell trafficking to peripheral lymph nodes. Recent studies have reported the expression of CCRL2 in different human cancer cell lines and tissues. However, its function and expression in prostate cancer has not been previously addressed.
Insights
Atypical chemokine receptor 5 (ACKR5/CCRL2) is overexpressed in prostate cancer. This finding suggests ACKR5/CCRL2 may play a role in prostate tumorigenesis and offers a potential therapeutic target.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Atypical chemokine receptors (ACKRs) modulate chemokine availability and function, influencing pathophysiological processes like tumorigenesis.
- The ACKR family includes five members: ACKR1/DARC, ACKR2/D6, ACKR3/CXCR7, ACKR4/CCRL1, and ACKR5/CCRL2.
- The role and expression of ACKR5/CCRL2 in prostate cancer have not been previously investigated.
Purpose of the Study:
- To investigate the differential expression of atypical chemokine receptors in prostate cancer.
- To specifically evaluate the expression and potential role of ACKR5/CCRL2 in prostate cancer development and progression.
Main Methods:
- Quantitative PCR was employed to assess the differential expression of all five ACKR family members in prostate cancer.
- Protein level analysis of ACKR5/CCRL2 was conducted in a metastatic prostate cancer cell line and patient-derived malignant tissues.
Main Results:
- Differential expression patterns of atypical chemokine receptors were observed in prostate cancer.
- ACKR5/CCRL2 was confirmed to be overexpressed at the protein level in a metastatic prostate cancer cell line.
- Elevated ACKR5/CCRL2 protein levels were also detected in malignant prostatic tissues from prostate cancer patients.
Conclusions:
- ACKR5/CCRL2 is overexpressed in prostate cancer, indicating its potential involvement in the disease.
- These findings highlight ACKR5/CCRL2 as a potential biomarker or therapeutic target for prostate cancer.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Types of Receptors: Cell Surface Receptors
Internal Receptors
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
G-protein Coupled Receptors

